


# Use of Lornoxicam against Alzheimer's Disease\*

## The innovation

It has been found that peripheral platelets are the primary source of amyloid beta 1-42 peptide deposited in the cerebral plaques. With this finding, Alzheimer's Disease (AD) is to be defined as a vascular disease. Likewise, it has been known that non steroidal anti-inflammatory drugs (NSAIDs) have an influence on APP protein expression and processing in that they reduce the Prostaglandin E2-induced APP expression and at the same time cause changes in the cleavage of APP. Epidemiological studies have brought the interesting result that the use of NSAIDs is associated with a significantly lower risk to develop AD. Therefore the presented technology focuses on one representative of NSAIDs.

The use of Lornoxicam - a well-known NSAID - for the treatment of AD is manifold because of:

- its balanced inhibition of Cox-1 and Cox-2 with a higher inhibition coefficient for Cox-1
- its influence on APP (amyloid precursor protein) processing in neuronal cell lines
- its ability to lower the release of amyloid beta 1-42 peptide through the blood-brain barrier (sink effect)
- its ability to lower the occurrence of non-amyloid sAPP alpha standing for a neuroprotective effect



## Advantages at a glance

- 2nd indication (Lornoxicam has been in use as an anti-inflammatory drug since many years and is approved in several countries for marketing)
- No safety-relevant undesirable side effects expected
- Clinical trial phase II in progress

## Keywords

- Alzheimer's Disease
- APP (amyloid precursor protein)
- Non steroidal anti-inflammatory drugs (NSAIDs)
- Amyloid peptides and plaques
- Sink effect
- Clinical trial phase II

To acquire a licence for this new technology, please don't hesitate to contact us!

## Areas of application

- Drug candidate against Alzheimer's Disease in advanced development status
- 2nd indication for a non steroidal anti-inflammatory drug

## Patent status

The invention is filed internationally and partially granted. It is owned by Dritte Patentportfolio Beteiligungsgesellschaft mbH & Co. KG. The application was filed in May 2003.



### IP Bewertungs AG (IPB)

Stephansplatz 10  
20354 Hamburg  
Germany

Dr Atilla Coksezen  
Ref. no. 001951

Tel +49 (0)40 8787 90-00  
Fax +49 (0)40 8787 90-01

BIOTECHPHARMA@IPB-AG.com  
www.IPB-AG.com